Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Chiang, Kun Chun ^a   Tsui, Ke Hung ^a   Chung, Li Chuan ^b   Yeh, Chun Nan ^a   Feng, Tsui Hsia ^b   Chen, Wen Tsung ^c   Chang, Phei Lang ^a   Chiang, Hou Yu ^b   Juang, Horng Heng ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL KAOHSIUNG UNIVERSITY OF HOSPITALITY AND TOURISM   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BTG2 PROTEIN, HUMAN; CISPLATIN; IMMEDIATE EARLY PROTEIN; NF-KAPPA B KINASE; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMEDIATE-EARLY PROTEINS; MALE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84903731937     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05511     Document Type: Article

References (43)

1. Siegel, R.,Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA CancerJ Clin 62, 10-29 (2012).
2. Han, M., Partin, A. W., Pound, C. R., Epstein, J. I. & Walsh, P. C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. (Pubitemid 32916759)
3. D'Amico, A. V., Cote, K., Loffredo, M., Renshaw, A. A. & Schultz, D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20, 4567-4573 (2002). (Pubitemid 35402960)
4. Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-1883 (2012).
5. Prestayko, A. W., D'Aoust, J. C., Issell, B. F. & Crooke, S. T. Cisplatin (cisdiamminedichloroplatinum II). Cancer Treat Rev 6, 17-39 (1979).
6. Dhar, S., Kolishetti, N., Lippard, S. J. & Farokhzad, O. C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A 108, 1850-1855 (2011).
7. Siddik, Z. H. Cisplatin:mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 (2003). (Pubitemid 37487159)
8. Tirone, F. The gene PC3(TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair? J Cel Physiol 187, 155-165 (2001). (Pubitemid 32270074)
9. Lim, I. K. TIS21 (/BTG2/PC3) as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule. J Cancer Res Clin Oncol 132, 417-426 (2006).
10. Rouault, J. P. et al. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 14, 482-486 (1996).
11. Cortes, U. et al. BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. Mol Carcinog 27, 57-64 (2000). (Pubitemid 30090587)
12. Ryu, M. S. et al. TIS21/BTG2/PC3 is expressed through PKC-delta pathway and inhibits binding of cyclin B1-Cdc2 and its activity, independent of p53 expression. Exp Cell Res 299, 159-170 (2004). (Pubitemid 39078391)
13. Tsui, K. H.,Hsieh,W. C., Lin, M. H., Chang, P. L. & Juang, H. H. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate 68, 610-619 (2008).
14. Chiang, K. C. et al. Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells. PLoS One 9, e89117 (2014).
15. Eastman, A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34, 155-166 (1987). (Pubitemid 17149009)
16. Rossi, A.,Maione, P. & Gridelli, C. Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients. Expert Opin Drug Saf 4, 1051-1067 (2005). (Pubitemid 41671603)
17. Jiang, T. et al. Enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated Salmonella carrying a plasmid co-expressing p53 gene and mdm2 siRNA. Cancer Lett 337, 133-142 (2013).
18. Xu, X. et al. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci U S A 110, 18638-18643 (2013).
19. Tsui, K. H., Chang, P. L., Lin, H. T. & Juang, H. H. Down-regulation of the prostate specific antigen promoter by p53 in human prostate cancer cells. J Urol 172, 2035-2039 (2004).
20. Tsui, K. H., Feng, T. H., Lin, Y. F., Chang, P. L. & Juang, H. H. p53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells. Prostate 71, 62-70 (2011).
21. Mantoni, T. S., Reid, G. & Garrett, M. D. Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner. Oncogene 25, 3139-3149 (2006). (Pubitemid 43881555)
22. Sukhatme, V. P. et al. A novel early growth response gene rapidly induced by fibroblast, epithelial cell and lymphocyte mitogens. Oncogene Res 1, 343-355 (1987). (Pubitemid 18046336)
23. Fletcher, B. S. et al. Structure and expression of TIS21, a primary response gene induced by growth factors and tumor promoters. J Biol Chem 266, 14511-14518 (1991). (Pubitemid 21907533)
24. Chung, L. C. et al. L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells. Am J Physiol Cell Physiol 302, C676-685 (2012).
25. Tsui, K. H., Chung, L. C., Feng, T. H., Chang, P. L. & Juang, H. H. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells. Int J Cancer 130, 2812-2823 (2012).
26. Zhang, L., Huang, H.,Wu, K.,Wang, M. & Wu, B. Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro. Mol Biol Rep 37, 2579-2586 (2010).
27. Elmore, L. W., Di, X., Dumur, C., Holt, S. E. & Gewirtz, D. A. Evasion of a singlestep, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. Clin Cancer Res 11, 2637-2643 (2005). (Pubitemid 40569464)
28. Hoffman, K. L., Lerner, S. P. & Smith, C. L. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Horm Cancer 4, 24-35 (2013).
29. Sasajima, H., Nakagawa, K. & Yokosawa, H. Antiproliferative proteins of the BTG/Tob family are degraded by the ubiquitin-proteasome system. Eur J Biochem 269, 3596-3604 (2002). (Pubitemid 34989004)
30. Loeb, S., Carter, H. B., Catalona, W. J., Moul, J. W. & Schroder, F. H. Baseline prostate-specific antigen testing at a young age. Eur Urol 61, 1-7 (2012).
31. Fitzpatrick, J. M., Banu, E. & Oudard, S. Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int 103, 578-587 (2009).
32. Niu, Y. et al. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res 68, 7110-7119 (2008).
33. Vukmirovic-Popovic, S., Escott, N. G. & Duivenvoorden, W. C. Presence and enzymatic activity of prostate-specific antigen in archival prostate cancer samples. Oncol Rep 20, 897-903 (2008).
34. Cronauer, M. V., Schulz, W. A., Burchardt, T., Ackermann, R. & Burchardt, M. Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 23, 3541-3549 (2004). (Pubitemid 38658420)
35. Hu, X. D. et al. BTG2 is an LXXLL-dependent co-repressor for androgen receptor transcriptional activity. Biochem Biophys Res Commun 404, 903-909 (2011).
36. Duriez, C. et al. The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene 282, 207-214 (2002). (Pubitemid 34117577)
37. Basseres, D. S. & Baldwin, A. S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25, 6817-6830 (2006). (Pubitemid 44657854)
38. Napetschnig, J. & Wu, H. Molecular basis of NF-kappaB signaling. Annu Rev Biophys 42, 443-468 (2013).
39. Baud, V. & Karin, M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8, 33-40 (2009).
40. Pomerantz, J. L. & Baltimore, D. Two pathways to NF-kappaB. Mol Cell 10, 693-695 (2002).
41. Kasparkova, J. et al. Different affinity of nuclear factor-kappa B proteins to DNA modified by antitumor cisplatin and its clinically ineffective trans isomer. FEBS J 281, 1393-1408 (2014).
42. Kwon, Y. K., Jun, J.M., Shin, S.W., Cho, J. W. & Suh, S. I. Curcumin decreases cell proliferation rates through BTG2-mediated cyclin D1 down-regulation in U937 cells. Int J Oncol 26, 1597-1603 (2005).
43. Kawakubo, H. et al. Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer. Oncogene 23, 8310-8319 (2004). (Pubitemid 39531842)